SWOG clinical trial number
SWOG-8569

Therapy of Metastatic Malignant Melanoma with Recombinant Human Interleukin-2.

Closed
Phase
Published
Abbreviated Title
Therapy of Metastatic Malignant Melanoma with Recombinant Human Interleukin-2.
Activated
08/01/1986
Closed
10/01/1988

Publication Information Expand/Collapse

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

2001

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

JM Unger;LE Flaherty;PY Liu;KS Albain;VK Sondak Cancer 91(6):148-1155

1991

A phase II study of IV bolus recombinant interleukin 2 in advanced malignant melanoma: A Southwest Oncology Group study.

RP Whitehead;KJ Kopecky;MK Samson;JJ Costanzi;RB Natale;LG Feun;EM Hersh;JJ Rinehart JNCI 83(17):1250-1252

1989

A phase II study of IV bolus recombinant interleukin 2 (IL-2) inmetastatic malignant melanoma: A Southwest Oncology Group study

RP Whitehead;KJ Kopecky;MK Samson;JJ Costanzi;R Natale;L Feun;EM Hersh ASCO 8:284(#1108)